phrykt

Ocugen, Inc. (OCGN): who owns it and who trades it

As of Nov 16, 2026, OCGN insiders reported 4 open-market sales worth $1.1M and 1 purchase worth $25.8K in the last 12 months, with 100% of the sale value made under pre-set 10b5-1 plans. The largest seller was Shankar Musunuri (CEO), with $1.1M. 2 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Ocugen

From the latest filings

Overall: more buying than selling. Funds and insiders mostly bought. Famous investors was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns OCGN

148 funds and institutions reported OCGN shares worth $224M at the end of Q2 2026, about 43% of the company. The largest holder is BlackRock, Inc. with 8.0%.

Funds and institutions (13F) 43%Everyone else 57%

10 largest owners, by share of the company

BlackRock, Inc.8.0%
State Street Corp6.3%
Vanguard Capital Management LLC4.2%
Millennium Management LLC4.1%
Geode Capital Management, LLC2.6%
Rtw Investments, LP2.0%
UBS Group AG1.5%
Ikarian Capital, LLC1.2%
GMT Capital Corp1.0%
Marshall Wace, LLP1.0%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
BlackRock, Inc.27.00M7.98%$41.3M+270%
State Street Corp21.47M6.34%$32.8M+122%
Vanguard Capital Management LLC14.37M4.25%$22M+4%
Millennium Management LLC13.94M4.12%$21.3M+2%
Geode Capital Management, LLC8.87M2.62%$13.6M+110%
Rtw Investments, LP6.67M1.97%$10.2MNo change
UBS Group AG5.18M1.53%$7.9M-29%
Ikarian Capital, LLC3.96M1.17%$6.1MNo change
GMT Capital Corp3.51M1.04%$5.4MNo change
Marshall Wace, LLP3.41M1.01%$5.2M-58%
Vanguard Portfolio Management LLC3.33M0.98%$5.1M+256%
Hennion & Walsh Asset Management, Inc.2.83M0.84%$4.3M+122%
Northern Trust Corp2.75M0.81%$4.2M+285%
Vanguard Fiduciary Trust Co2.37M0.70%$3.6M+18%
Two Sigma Investments, LP2.23M0.66%$3.4M-1%
Qube Research & Technologies Ltd2.20M0.65%$3.4M-42%
Bank of America Corp1.99M0.59%$3M+70%
Hrt Financial LP1.77M0.52%$2.7M+370%
Boothbay Fund Management, LLC1.10M0.32%$1.7MNo change
Charles Schwab Investment Management Inc1.04M0.31%$1.6M+392%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, OCGN insiders reported $25.8K of open-market purchases and $1.1M of sales. 100% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$25.8K
1 trades, 1 people
Sales, 12 months
$1.1M
4 trades, 1 people
Sales under a 10b5-1 plan
100%
Share of sale value
Latest trade
Oct 9, 2026
Filed Oct 13, 2026

Purchases and sales by month

$589K$589KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Oct 9, 2026Shankar MusunuriCEOSale plan468,727$0.95$445KForm 4
Oct 9, 2026Shankar MusunuriCEOSale plan57,264$0.95$54.4KForm 4
Sep 9, 2026Shankar MusunuriCEOSale plan468,727$1.12$525KForm 4
Sep 9, 2026Shankar MusunuriCEOSale plan57,264$1.12$64.1KForm 4
Jun 15, 2026Treerita Essalima Johnson-GreeneCFOPurchase21,000$1.23$25.8KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Shankar MusunuriChief Executive Officer, Director–$1.1MOct 9, 2026
Treerita Essalima Johnson-GreeneChief Financial Officer$25.8K–Jun 15, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

OCGN short interest

Very high short interest. 31.7% of OCGN shares are sold short: about 1 share in 3. Over the last 12 reports the number of shares short went up 33%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 107.67M OCGN shares were sold short, 31.7% of the shares outstanding, up 0.5% from the report before. At the average daily volume of 6.56M shares, buying them all back would take about 16.4 trading days (days to cover).

Shares short, % of all shares

31.7%May 15Oct 3032.9%

Days to cover

16.4May 15Oct 3031.4

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 2026107.67M31.73%+0%6.56M16.4
Oct 15, 2026107.16M31.60%+5%6.79M15.8
Sep 30, 2026102.05M30.09%-4%7.47M13.7
Sep 15, 2026106.06M31.28%+8%10.21M10.4
Aug 31, 202698.31M28.99%-3%3.48M28.2
Aug 14, 2026101.77M30.01%+1%4.26M23.9
Jul 31, 2026100.91M29.76%+0%4.68M21.6
Jul 15, 2026100.59M29.71%-5%5.34M18.9
Jun 30, 2026105.43M31.14%+22%14.92M7.1
Jun 15, 202686.56M25.57%+4%4.68M18.5
May 29, 202683.02M24.52%+2%5.80M14.3
May 15, 202681.05M23.94%+16%9.93M8.2

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Ocugen company events

Ocugen filed 26 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership). The latest was on Nov 10, 2026.

  1. Nov 10, 2026AgreementOcugen, Inc. entered into an Exclusive License Agreement with Celairis Therapeutics Holdings Pty Ltd, pursuant to which Celairis was granted an exclusive, non-sublicensable, royalty-bearing license to (i) import, export, distribute, use, have used, keep, sell, have sold, or offer for sale… Filing
  2. Nov 4, 2026ResultsReleased financial results. Filing
  3. Oct 15, 2026AnnouncementShared information with investors. Filing
  4. Oct 15, 2026AgreementOcugen, Inc. entered into an Exclusive License Agreement with Roots Pharmaceutical Company WLL, pursuant to which Roots was granted an exclusive, non-sublicensable, royalty-bearing license to (i) make, have made, manufacture, import, export, distribute, use, have used, keep, sell, have sold, or… Filing
  5. Oct 6, 2026VoteReported shareholder vote results. Filing
  6. Sep 23, 2026VoteReported shareholder vote results. Filing
  7. Sep 8, 2026AnnouncementThe Company announced that the first patient was dosed in the global Phase 3 registrational trial of OCU410 (AAV5-hRORA), its first-in-class modifier gene therapy candidate for Geographic Atrophy secondary to dry age-related macular degeneration. Filing
  8. Aug 6, 2026ResultsReleased financial results. Filing
  9. Jul 13, 2026AnnouncementOcugen, Inc. issued a press release announcing that it signed a binding term sheet for the license of OCU400 modifier gene therapy for retinitis pigmentosa in the Middle East and North Africa. Filing
  10. Jun 11, 2026AnnouncementAs previously reported, effective May 8, 2026, the Company appointed Mohamed Genead, M.D., M.Sc., as Acting/Interim Chief Medical Officer. Filing
  11. Jun 3, 2026LeadershipRamesh Ramachandran, CPA, MBA, CMA, resigned as the Chief Accounting Officer of Ocugen, Inc. Filing
  12. May 14, 2026LeadershipHuma Qamar, M.D., MPH, CMI, separated from Ocugen, Inc. as its Chief Medical Officer. Filing
  13. May 14, 2026DebtTook on new debt. Filing
  14. May 7, 2026AgreementOcugen, Inc. completed its previously announced private offering of $115.0 million of 6.75% Convertible Senior Notes due 2034. Filing
  15. May 5, 2026AnnouncementThe Company announced the pricing of its previously announced private offering of $115.0 million of 6.75% Convertible Senior Notes due 2034. Filing
  16. May 4, 2026AnnouncementThe Company issued a press release announcing the Offering. Filing
  17. Mar 27, 2026AnnouncementShared information with investors. Filing
  18. Mar 24, 2026AnnouncementShared information with investors. Filing
  19. Mar 20, 2026AnnouncementAs previously disclosed, in August 2025, Ocugen, Inc. closed a registered direct offering, pursuant to a securities purchase agreement with an institutional investor, for the purchase and sale of 20,000,000 shares of common stock, $0.01 par value per share, and warrants to purchase up to an… Filing
  20. Mar 4, 2026AnnouncementOcugen, Inc. filed a petition in the Court of Chancery of the State of Delaware pursuant to Section 205 of the Delaware General Corporation Law seeking validation of the Certificate of Amendment (as defined below), increasing the Company’s number of authorized shares of common stock, and all shares… Filing
  21. Mar 4, 2026ResultsReleased financial results. Filing
  22. Feb 9, 2026LeadershipOcugen, Inc. announced the appointment of Rita Johnson-Greene as the Company’s Chief Financial Officer, effective February 9, 2026. Filing
  23. Jan 23, 2026AnnouncementThe Company closed the Offering and anticipates the proceeds from the Offering will extend its cash runway into the fourth quarter of 2026. Filing
  24. Jan 21, 2026AgreementOcugen, Inc. entered into an underwriting agreement with Oppenheimer & Co. Inc., pursuant to which the Company agreed to issue and sell to the Underwriter, in an offering 15,000,000 shares of the Company’s common stock, par value $0.01 per share, at an offering price of $1.50 per share. Filing
  25. Jan 15, 2026AnnouncementOcugen, Inc. issued a press release announcing positive preliminary 12-month data from both its Phase 1 and Phase 2 ArMaDa trials evaluating OCU410 (AAV5-RORA), its novel modifier gene therapy for geographic atrophy secondary to dry age-related macular degeneration. Filing
  26. Dec 18, 2025LeadershipIn the fourth quarter of 2025, the Compensation Committee of the Board of Directors of Ocugen, Inc. conducted a review, with its compensation consultant, of total equity ownership of the Company’s Chief Executive Officer, Dr. Shankar Musunuri, as compared to founder chief executive officers in the… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Ocugen financials

Famous investors that hold OCGN

2 of the 50 well-known investors we track reported holding OCGN in their latest 13F filing. The largest position is Israel Englander's, worth $12.5M.

FundQuarterSharesValueOf portfolioChange
Israel Englander · Millennium ManagementQ3 202612.18M$12.5M0.0%-13%
Steve Cohen · Point72 Asset ManagementQ3 2026525,781$542K0.0%+10%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about Ocugen, Inc. (OCGN) stock

Who owns the most OCGN stock?

The largest reported owner of Ocugen, Inc. (OCGN) is BlackRock, Inc., with 8.0% of the company. In total, 148 funds and institutions reported holding OCGN at the end of Q2 2026, together about 43% of the shares. See the largest owners.

Are OCGN insiders buying or selling?

In the last 12 months, OCGN insiders reported 1 open-market purchase worth $25.8K and 4 sales worth $1.1M. The latest trade was on Oct 9, 2026. See every trade.

What is the short interest in OCGN?

As of Oct 30, 2026, 107.67M OCGN shares were sold short, 31.7% of the shares outstanding, up 0.5% from the report before. At the average daily volume of 6.56M shares, buying them all back would take about 16.4 trading days (days to cover). See the history.

Which famous investors hold OCGN?

2 of the 50 well-known investors we track reported OCGN in their latest 13F filing, including Israel Englander, Steve Cohen. The largest position is worth $12.5M. See all holders.

Executive pay

Ocugen's chief executive was paid a total of $4.8M for the year ended Dec 31, 2025, up 149% from $1.9M the year before. In the last 12 months, Ocugen's executives and directors bought $25.8K of stock on the open market and sold $1.1M.

Chief executive, total pay$4.8MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$6.3MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$2.1MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.